University Hospitals Birmingham NHS Foundation Trust

Chapters

StatusDrug nameNICE TAsComments
Status: RedAlemtuzumab concentrate for infusion

Hospital use only

Status: RedAnti-thymocyte globulin (equine) injection
Status: RedAnti-thymocyte globulin (rabbit) injection
Status: RedAtezolizumab (Tecentriq®)
Status: RedAvacopan (Tavneos®)
Status: RedAvatrombopag
Status: RedAvelumab (Bavencio®)
Status: RedAxicabtagene ciloleucel  (Yescarta®)
Status: RedAzathioprine injection

For hospital use only

Status: RedAzathioprine suspension
Status: RedAzathioprine tablets
Status: RedBasiliximab injection

For hospital use only

Status: RedBCG bladder instillation

For hospital use only

Status: RedBelatacept powder concentrate for infusion

For hospital use only

Status: RedCiclosporin capsules (Neoral)

New post transplant

Status: AmberCiclosporin capsules (Neoral)

Post-transplant pre 2013

Status: RedCiclosporin concentrate for infusion
Status: RedCiclosporin solution (Neoral) 50ml

New post transplant

Status: AmberCiclosporin solution (Neoral) 50ml

Post-transplant pre 2013

Status: RedDaclizumab concentrate for infusion

For Hospital Use Only. Please see drug safety alert.

Safety alert

Status: RedDimethyl fumarate
Status: RedDiroximel fumarate
Status: RedFingolimod capsules
Status: RedGemtuzumab ozogamicin
Status: RedGlatiramer injection
Status: RedImlifidase
Status: RedInotuzumab ozogamicin (Besponsa®)
Status: RedInterferon Alfa-2A injection
Status: RedInterferon Alfa-2B pen
Status: RedInterferon beta
Status: RedInterferon gamma

For hospital use only

Status: RedLenalidomide capsules
Status: RedMifamurtide

For hospital use only

Status: AmberMycophenolate mofetil capsules
Status: RedMycophenolate mofetil injection
Status: RedMycophenolate mofetil suspension

New post-transplant

Status: AmberMycophenolate mofetil suspension

Post-transplant pre 2013

Status: RedMycophenolate mofetil tablets

New post transplant

Status: AmberMycophenolate mofetil tablets

Post-transplant pre 2013

Status: RedNatalizumab injection

For hospital use only

Status: RedOcrelizumab
Status: RedOfatumumab

For hospital use only

Status: RedOfatumumab (Kesimpta®)
Status: RedPeginterferon Alfa-2A (Pegasys)

Myeloproliferative neoplasia (MPN)

Status: RedPeginterferon Alfa-2B prefilled pen
Status: RedPeginterferon beta-1a
Status: RedPomalidomide

Hospital use only

Status: RedRituximab
Status: RedSarilumab
Status: RedSirolimus solution

New post-transplant

Status: AmberSirolimus solution

Post-transplant pre 2015

Status: RedSirolimus tablets

New post-transplant

Status: AmberSirolimus tablets

Post-transplant pre 2015

Status: RedTacrolimus capsules (Prograf)

New post-transplant

Status: AmberTacrolimus capsules (Prograf)

Post-transplant pre 2015

Status: RedTacrolimus prolonged release capsules (Advagraf)

New post-transplant

Status: AmberTacrolimus prolonged release capsules (Advagraf)

Post-transplant pre 2015

Status: RedTeriflunomide
Status: RedThalidomide capsules

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.

Building healthier lives
Back to top